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ABSTRACT European Respiratory Society (ERS) guidelines recommend the assessment of patients with
interstitial lung disease (ILD) and severe pulmonary hypertension (PH), as defined by a mean pulmonary
artery pressure (mPAP) ⩾35 mmHg at right heart catheterisation (RHC). We developed and validated a
stepwise echocardiographic score to detect severe PH using the tricuspid regurgitant velocity and right
atrial pressure (right ventricular systolic pressure (RVSP)) and additional echocardiographic signs.
Consecutive ILD patients with suspected PH underwent RHC between 2005 and 2015. Receiver
operating curve analysis tested the ability of components of the score to predict mPAP ⩾35 mmHg, and a
score devised using a stepwise approach. The score was tested in a contemporaneous validation cohort.
The score used “additional PH signs” where RVSP was unavailable, using a bootstrapping technique.
Within the derivation cohort (n=210), a score ⩾7 predicted severe PH with 89% sensitivity, 71%
specificity, positive predictive value 68% and negative predictive value 90%, with similar performance in
the validation cohort (n=61) (area under the curve (AUC) 84.8% versus 83.1%, p=0.8). Although RVSP
could be estimated in 92% of studies, reducing this to 60% maintained a fair accuracy (AUC 74.4%).
This simple stepwise echocardiographic PH score can predict severe PH in patients with ILD.
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ORIGINAL ARTICLE
INTERSTITIAL LUNG DISEASE
Introduction
Interstitial lung diseases (ILDs) are commonly associated with the development of pulmonary
hypertension (PH-ILD) [1–3]. There appears to be no clear correlation between the severity of ILD and
PH according to pulmonary function indices or extent of fibrosis on computed tomography [2, 4],
suggesting the presence of an exaggerated vascular phenotype. PH-ILD impacts negatively on symptoms
and prognosis [2, 5, 6], including survival after lung transplantation [7, 8]. This is especially true for
patients with severe PH, defined as mean pulmonary arterial pressure (mPAP) ⩾35 mmHg on right heart
catheterisation (RHC), in whom prognosis is particularly poor [9]. Current European Respiratory Society
(ERS)/European Society of Cardiology (ESC) PH guidelines recommend that patients with severe PH-ILD
should be identified and referred to specialist centres with expertise in both chronic lung disease and PH
[10], where they may be considered for pulmonary vasodilator therapy on an individual basis, or entered
into clinical trials.
Echocardiography is key in the identification of patients with PH who should be referred for RHC.
According to ESC/ERS guidelines, estimation of PH by echocardiography should be based upon
assessment of peak tricuspid regurgitation velocity (TRV) in addition to “additional echocardiographic PH
signs” [10]. Previous echocardiographic studies in ILD patients highlight that the use of TRV or right
ventricular systolic pressure (RVSP) can under- and overestimate PH [11]. Relying on RVSP alone may be
unhelpful in ILD patients, as this value could not be obtained in 44–55% of previous studies [11, 12].
Therefore, we sought to evaluate the role of “additional” echocardiographic PH signs in risk-stratifying
ILD patients for the presence of severe PH. We developed and validated a stepwise echocardiographic
score. In addition, we tested the accuracy of the score when TRV was unavailable.
Methods
Consecutive ILD patients referred to the Royal Brompton Hospital National Pulmonary Hypertension
Service (London, UK) with suspected PH between 2005 and 2015 were reviewed, with demographics and
ILD diagnosis collected (figure 1). Patients with echocardiograms performed >6 months from RHC were
excluded, as were those with high-resolution computed tomography (HRCT) demonstrating absent or
trivial interstitial fibrosis. If patients within the study received PH therapies following the RHC, only the
echocardiogram prior to the RHC was used in the analysis. This study had institutional ethics review
board approval (Royal Brompton, Harefield reference 2016PH002B).
Echocardiography
The following echocardiographic parameters were evaluated: 1) “pressure domains”: TRV, RVSP, early
diastolic pulmonary regurgitation velocity, right atrial pressure (RAP) and pulmonary valve acceleration
time; 2) “right ventricle (RV) morphology domains”: RV:left ventricle (LV) basal diameter ratio, right
atrial (RA) size and LV eccentricity index (a measure of septal flattening); and 3) “RV function domains”:
tricuspid annular plane systolic excursion (TAPSE) and fractional area change (percentage change in RV
area between end-diastole and end-systole).
Images were acquired using a 3-MHz frequency harmonic phased-array transducer. Doppler
echocardiography was performed as per the American Society of Echocardiography recommendations [13,
14]. The two-dimensional echo datasets were interpreted by cardiologists with advanced echocardiography
training. Briefly, the maximum RV to RA pressure difference was derived from the peak velocity of
tricuspid regurgitation using the simplifed Bernoulli equation. RA pressure was based on inferior vena
cava diameter and respiratory collapse. RVSP was estimated by adding RAP to the RV and RA pressure
differential. Further explanation of echocardiographic parameters is provided in the online supplementary
material.
Right heart catheterisation
RHC was performed using standard techniques [10] with haemodynamic measurements obtained at rest
in all patients. Cardiac output was measured using the indirect Fick method with oxygen consumption
estimated using the LaFarge equation. Pulmonary vascular resistance (PVR) was calculated as (mPAP –
pulmonary capillary wedge pressure)/cardiac output.
Pulmonary function testing
Pulmonary function testing (PFT) was performed with predicted values calculated using American
Thoracic Society/ERS criteria [15]. Measurements performed included spirometric [16] and single-breath
transfer factor of the lung for carbon monoxide and transfer coefficient of the lung for carbon monoxide
adjusted for alveolar volume [17].
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Computed tomography analysis
Computed tomography was performed at full inspiration in the supine position. Images were interpreted
by two radiologists blinded to the clinical data. High-resolution reconstructions were reviewed to estimate
interstitial disease extent. Severity of fibrosis was scored as limited (<20%) or extensive (>20%) [18].
Conflict of extent of fibrosis by the reviewers of more than one point was resolved by consensus.
Generation of the echocardiographic score
Echocardiographic variables used in the model were selected by expert opinion and according to ESC/ERS
guidelines, and the ability to predict severe PH was assessed by receiver operating curve (ROC) analysis.
The strongest predictors (area under the curve (AUC) >70%) were incorporated into a contingent stepwise
model to predict severe PH. Threshold values of each individual variable were chosen a priori, again based
upon expert consensus and guidelines. Each variable was entered into the score as a binary or categorical
variable depending on the threshold value. The weighting of each threshold within the score was
determined by choosing a model with optimal AUC with 900000 different score combinations analysed
(table 1). A contingent stepwise method was used to allow for missing data, and was designed to be easy
to use with the strongest most available predictors used upfront in the score. This was to facilitate rapid
staging of severe PH (figure 2). For example, when the strongest predictor of severe PH was present and
the highest threshold was met, the score was positive. Where data was missing or in lower risk categories,
the stepwise score was designed to be performed in sequence until a threshold for severe PH is reached or
all available variables analysed. The threshold for the echocardiographic score becoming positive (and
severe PH likely) was determined by the score, which offered the best balance of sensitivity and specificity.
Once the threshold is met, no further analysis is needed. The derivation cohort included patients with all
noninvasive assessments performed at RHC, and the validation cohort were missing either brain
natriuretic peptide (BNP) or PFTs at RHC. The composite echocardiographic score was derived and tested
within the derivation cohort, and tested in the validation cohort.
Clinical suspicion of PH-ILD
2005–2015
n=703
Corresponding RHC
n=340
Baseline noninvasive investigations
performed within 6 months of
baseline RHC
(CT, echo, BNP, PFT)
n=210
Baseline echocardiogram
performed within 6 months 
of RHC
Missing one baseline 
investigation
(CT, BNP, PFT)
n=61
No RHC
n=363
Excluded
Echocardiogram >6
months after RHC 
(n=39)
Group 1 or 4
cause of PH
(n=5)
Trivial ILD at HRCT
(n=25)
Total
n=69
Echocardiograms scored by reviewer blinded to 
PH status and clinical outcome
Composite echo score
derived and tested
Composite echo score
tested within validation
FIGURE 1 Cohort identification and exclusion. A flow diagram describing the methodology of the study, from
patient identification and selection to the development and validation of the echocardiography (echo) score in
the derivation (n=210) and validation (n=61) cohorts; the latter derived from the same population over the
same time period, but with some missing brain natriuretic peptide (BNP) and pulmonary function testing
(PFT) data from the time of right heart catheterisation (RHC). CT: computed tomography; PH: pulmonary
hypertension; ILD: interstitial lung disease; HRCT: high-resolution CT.
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Finally, the cohorts were combined for a post hoc analysis evaluating the effect of increasing RVSP (or
TRV) unavailability (in effect, blinding available data) to check the integrity of the score with unavailable
RVSP, as seen in historic cohorts. The echocardiographic score was evaluated using a bootstrapping
method, which randomly blinded available RVSP at each percentage point from 8% missing RVSP data (as
was found in our cohort) up to 60% (as seen in historic cohorts [11, 12]). 100 iterations were performed at
each percentage missing RVSP data between 8% and 60%, with random patient selection for RVSP
blinding at each iteration. The same method was used to compare the sensitivity of the stepwise
echocardiographic score to using RVSP alone (using a threshold of RVSP 64 mmHg) (figure 2).
Statistical analysis
All statistical analysis was performed using R version 3.3.1 (R Foundation for Statistical Computing; www.
r-project.org). Data were summarised as n (%) for categorical variables and mean±SD or median
(interquartile range) for continuous variables, as appropriate. Continuous variables were compared
between groups using ANOVA for parametric data and Kruskal–Wallis test for nonparametric data, or the
Wilcoxon signed-rank test or t-test, as appropriate. For categorical variables, a Chi-squared test was used.
Results
Patient demographics and ILD diagnosis
The derivation cohort consisted of 210 patients, with a mean age of 61±11 years, 55% of whom were male.
ILD diagnoses included idiopathic pulmonary fibrosis (IPF; n=62), connective tissue disease
(CTD)-associated ILD (n=59), sarcoidosis (n=43), chronic hypersensitivity pneumonitis (n=16), idiopathic
nonspecific interstitial pneumonitis (n=16) and “other ILD” (n=14), including unclassifiable ILD (four out
TABLE 1 Threshold values of individual variables within the composite echocardiographic
score, and the final score based upon area under the curve (AUC) analysis
Score Permutations Score
Minimum Maximum
RV systolic pressure mmHg
>64 4 8 5 7
>35 1 5 5 1
⩽35 or NA 0 0 1 0
Right atrial area cm2
>25 3 7 5 6
>20 1 2 4 1
⩽20 or NA 0 0 1 0
Early diastolic pulmonary regurgitation velocity mmHg
>36 4 8 5 4
⩾20 1 3 3 3
<20 or NA 0 0 1 0
RV fractional area change %
<35 1 5 5 4
⩾35 0 0 1 0
RV/LV short axis dimension
>1 1 6 6 3
⩽1 or NA 0 0 0 0
Systolic eccentricity index
⩾1.1 1 4 4 1
<1.1 or NA 0 0 1 0
Total permutations n 900000
Maximum score 25
Each component of the composite score was selected as that having the highest AUC to predict pulmonary
hypertension using receiver operating curve analysis (figure 1 and online supplementary material) and
consensus. For example, for right ventricular systolic pressure (RVSP), a minimum score of 4 and a
maximum of 8 was set; this was done for each threshold and variable, thereby creating a stepwise score.
Different combinations of score components (n=900000) were then tested, and the model with the best
AUC chosen, which is displayed as the best score. The order of analysis using the echo composite score is
shown in the third column. For example, if a score of 7 was achieved at the first step (if RVSP >64 mmHg),
then the echo score became positive to predict severe PH, and no further analysis was needed. If the
RVSP was <64 mmHg, the second factor, right atrial area, was considered, and so on. RV: right
ventricular; NA: not available; LV: left ventricular.
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of 14) and smoking-related ILD (four out of 14). CTD-ILD included patients with scleroderma (36% of all
CTDs), undifferentiated CTD, rheumatoid arthritis (14%) and antisynthetase syndrome (14%), mixed
CTD (12%), Sjogren’s syndrome (5%) and systemic lupus erythematous (5%).
RHC and BNP data
RHC excluded PH (mPAP <25 mmHg) in 46 (22%) patients. PH was mild–moderate in severity (mPAP
25–34 mmHg) in 79 (38%) patients and severe (mPAP ⩾35 mmHg) in 85 (40%) patients. BNP increased
in a stepwise fashion across the groups (p<0.001 between groups). Patients with severe PH were younger
than patients with mild–moderate PH (p<0.001). More patients with sarcoidosis had severe PH (n=25,
58%) in the sarcoid group versus (n=60, 36%) in the nonsarcoid group (p=0.01) (table 2), but this was not
explained by sarcoidosis patients having more severe fibrosis at computed tomography or lung function
parameters.
Systolic pulmonary pressure
mmHg
>64
Score 7
36–64
Score 1
<36/NA
Score 0
Right atrial area
cm2
>25
Score 6
21–25
Score 1
≤20/NA
Score 0
Early diastolic pulmonary regurgitation velocity
m·s–1
≥3.0
Score 4
2.2–3.0
Score 3
Fractional area change
%
≤34
Score 4
>34/NA
Score 0
<2.2/NA
Score 0
RV:LV ratio
m·s–1
>1
Score 3
≤1/NA
Score 0
Eccentricity index
≥1.1
Score 1
<1.1/NA
Score 0
Severe PH point
Score ≥7
Severe PH likely
89% sensitivity
71% specificity
 If PAP >64 mmHg, 
score is positive, then no 
further analysis is necessary
 If score at any 
stage is ≥7 then score is 
positive and no further 
analysis is necessary
FIGURE 2 Severe pulmonary hypertension (PH) in interstitial lung disease (ILD) stepwise composite
echocardiographic score. If an overall score of ⩾7 is achieved, then the score is positive for the prediction of
severe PH with a mean pulmonary arterial pressure (PAP) ⩾35 mmHg. Where the right ventricular systolic
pressure (RVSP) is >64 mmHg, the score is positive and no further analysis is necessary. Where RVSP is not
available or intermediate then each step is continued until either a score of ⩾7 is achieved, or if the final
score is <7, in which case the score is negative and severe PH is unlikely. NA: not available; RV: right
ventricle; LV: left ventricle.
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Lung function and severity of fibrosis on computed tomography
Analysis of lung function parameters between subgroups of PH severity showed no significant difference
in spirometric values between groups, whereas there was a stepwise deterioration in gas transfer coefficient,
partial pressure of oxygen (capillary blood gas analysis) and alveolar–arterial gradient (ANOVA p<0.001
for all) as PH increased in severity. The extent of ILD, as scored on HRCT, was >20% in 86% of the
cohort, with no difference between the groups according to PH severity (p=0.2) (table 2).
Echocardiographic results
RVSP was detectable in 92% of studies (table 3). RVSP was most likely to be unmeasurable in individuals
with an ILD diagnosis of sarcoidosis, with 19% of individuals having inadequate TRV Doppler traces to
estimate RVSP, compared to only 5% in the remainder (p=0.002). All direct and indirect
echocardiographic measures reflecting elevated pulmonary pressure showed a stepwise increase as PH
severity increased across the three groups (table 3).
Performance of the composite echocardiographic score
The strongest predictors of severe PH on ROC analysis were selected for the composite stepwise
echocardiographic score (the score is outlined in figure 2). These included RVSP (AUC 80.1%), early
pulmonary regurgitation gradient (adding RAP, AUC 80.7%; without RAP, AUC 80.8%), right atrial area
(AUC 75.5%), TRV (AUC 77.1%), systolic RV:LV diameter on short axis view (AUC 77.5%), LV
eccentricity index (AUC 80.6%) and RV fractional area change (AUC 72%). Other parameters, including
pulmonary valve acceleration time and TAPSE, performed less well (online supplementary figure S1).
A score ⩾7 was identified as the threshold to balance sensitivity and specificity (sensitivity 89%, specificity
71%, PPV 68% and NPV 90%) to predict severe PH. Using this cut-off, the stepwise echocardiographic
score was positive in 54% of the derivation cohort. Of the patients who scored positive, 88% achieved this
TABLE 2 Baseline right heart catheter and noninvasive variables
Total derivation cohort mPAP <25 mmHg mPAP 25–34 mmHg mPAP ⩾35 mmHg p-value
Subjects 210 46 79 85
Age years 61±11 63±11 64±11 58±12 0.004
Male % 55 52 54 56 0.9
ILD diagnosis
CTD 59 (28) 15 (25) 21 (36) 23 (39) 0.7
Sarcoidosis 43 (20) 4 (9) 14 (33) 25 (58) 0.01
IPF 62 (29) 18 (29) 28 (45) 16 (26) 0.02
CHP 16 (8) 6 (38) 2 (12) 8 (50) 0.1
NSIP 16 (8) 2 (12) 8 (50) 6 (38) 0.5
Other ILD 14 (7) 1 (7) 6 (43) 7 (50) 0.4
Right heart catheter
mPAP mmHg 33±11 20±4 29±3 43±7 <0.001
PVR Wood units 6.0±3.6 2.6±1.5 4.6±1.8 8.8±3.8 <0.001
Cardiac output L·min−1·m−2 4.3±1.3 4.8±1.3 4.1±1.3 4.1±1.2 0.02
PCWP mmHg 10±5 8±5 10±5 11±5 0.008
BNP ng·L−1 102 (44–266) 48 (30–72) 90 (42–141) 241 (105–436) <0.001
Pulmonary function tests
FEV1 L 1.6±0.6 1.6±0.6 1.5±0.5 1.6±0.6 0.9
FEV1 % pred 58±18 62±21 57±17 57±17 0.2
FVC L 2.0±0.8 2.0±0.8 1.9±0.7 2.2±0.9 0.2
FVC % pred 60±20 61±22 59 ±18 62±22 0.7
TLCO % pred 25±10 28±10 25±9 24 ±10 0.04
KCO % pred 52±17 59±18 54±16 48±16 <0.001
PaO2 kPa 7.9±1.9 8.9±1.9 8.1±1.9 7.1±1.7 <0.001
CT scan
ILD extent <20%/>20% 14/86 15/85 19/81 9/91 0.2
Data are presented as n, mean±SD, n (%) or median (interquartile range), unless otherwise stated. mPAP: mean pulmonary pressure at right
heart catheterisation; ILD: interstitial lung disease; CTD: connective tissue disease; IPF idiopathic pulmonary fibrosis; CHP: chronic
hypersensitivity pneumonitis; NSIP: nonspecific interstitial pneumonia; PVR: pulmonary vascular resistance; PCWP: pulmonary capillary
wedge pressure; BNP: brain natriuretic peptide; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLCO: transfer factor of the
lung for carbon monoxide; KCO: transfer coefficient of the lung for carbon monoxide; PaO2 : arterial oxygen tension (by capillary blood gas
analysis); CT: computed tomography.
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on the first step due to a RVSP of >64 mmHg, such that further analysis was unnecessary. The second step
assessed right atrial area, resulting in a further 4.8% of patients reaching the threshold, such that 92.9% of
the patients became positive within two steps. The echocardiographic score correctly assigned 78% of
individuals to the correct PH status, having incorrectly assigned the absence of severe PH in 5% of the
cohort (false negatives) and a falsely assuming severe PH in 17% of the cohort (false positives).
To test the potential influence of disease subgroup on the score, the IPF, CTD-ILD and sarcoidosis patient
subgroups were individually removed from the total cohort, and the composite echocardiographic score
retested. The AUC of the score remained similar between disease subgroups (online supplementary figure S2).
The characteristics of the derivation and validation cohorts were similar in terms of haemodynamic, BNP
and lung function parameters (table 4). The performance of the score to predict severe PH remained
similar in the derivation and validation cohort (AUC 84.8% versus 83.1%, p=0.8).
Utility of the echocardiographic score when RVSP is unavailable
As TRV had been historically more difficult to measure compared to our cohort, we assessed the effect of
increasingly unmeasurable TRV (RVSP) on the performance of the score. The effect of inability to record
TRV on the echocardiographic score was modelled for prevalence of missing data (figure 3a). With
increasing number of patients missing TRV (8% to 60%), AUC did not drop significantly (84% as seen in
the original cohort to 79% with 60% unavailable). Moreover, there was a clear advantage in using the
composite echocardiographic score to predict severe PH, as opposed to TRV alone, especially with
increasing TRV unavailability (figure 3b).
Discussion
This validated stepwise echocardiographic score combines traditional assessment of RVSP and additional
echocardiographic PH variables to identify severe PH in ILD. We have shown that a contingent stepwise
echocardiographic score, using both RVSP as well as other PH echocardiographic signs of RV dysfunction,
can predict severe PH within a large cohort of ILD patients, with a high sensitivity and specificity. The
score performs well in a large representative validation cohort, and remains sensitive even when TRV is
unavailable.
Our cohort had a much higher rate of TRV availability (92%) compared to previous studies (discussed
later). However, we recognise that the detection of TRV may be lower in other centres, therefore we
demonstrated that the score remains accurate even when TRV is unavailable, using statistical modelling.
We showed that the use of additional PH parameters beyond TRV (RVSP) made the score even more
reliable than when only using TRV alone, and is in keeping with our clinical experience in other
subgroups of PH patients. A panel of PH physicians and echocardiologists decided upon the best
parameters to include in the stepwise echocardiographic score, based on a clinical and pathophysiological
approach, and consideration of the latest ERS/ESC guidelines of echocardiographic assessment of PH [10].
The scores for each parameter were then tested in the derivation cohort using bootstrapping to derive the
TABLE 3 Echocardiographic variables grouped according to severity of pulmonary hypertension at right heart catheterisation
(RHC)
Availability % Derivation
cohort, total
mPAP
<25 mmHg
mPAP
25–34 mmHg
mPAP
⩾35 mmHg
p-value
Subjects 228 46 79 85
TRVmax m·s−1 92 3.7±0.6 3.3±0.5 3.6±0.5 4.0±0.6 <0.001
RVSP mmHg 92 66±19 53±13 61±18 76±17 <0.001
Pulmonary acceleration time ms 93 77±18 82±17 80±19 70±14 <0.001
Systolic eccentricity index 82 1.4±0.4 1.1±0.2 1.2±0.3 1.6±0.5 <0.001
Early PRVmax m·s−1 20 2.5±0.5 2.0±0.3 2.3±0.5 2.7±0.4 0.001
RAP mmHg 99.5 5 (5–10) 5 (5–10) 5 (5–10) 10 (5–10) 0.008
Fractional area change % 93 37±8 41±8 39±7 34±8 <0.001
Right atrial area cm2 93 20±8 15±4 18±6 24±8 <0.001
TAPSE cm 92 1.8±0.5 1.9±0.4 1.9±0.5 1.7±0.4 <0.001
RV:LV short axis dimension ratio (systolic) 81 0.9 (0.7–1.4) 0.7 (0.6–0.9) 1.0 (0.6–1.1) 1.3 (0.9–2.0) <0.001
Data are presented as n, mean±SD or median (interquartile range), unless otherwise stated. mPAP: mean pulmonary pressure at RHC; TRVmax:
maximum tricuspid regurgitation velocity; RVSP: right ventricular systolic pressure; PRVmax: maximum diastolic pulmonary regurgitation
velocity; RAP: right atrial pressure; TAPSE: tricuspid annular plane systolic excursion; RV: right ventricular; LV: left ventricular.
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weighting of each variable within the score. Although the score has six steps, 93% of the cohort scored
positively by the second step. The additional steps within the score are necessary to identify individuals
with a missing TRV and are the reason for preserved sensitivity despite a reducing availability of RVSP,
which is a unique property of this score.
We have demonstrated that this score is valid for broad ILD populations in wider settings. This relates
firstly to the used of standardised echocardiographic PH and RV parameters, which can be widely utilised.
Secondly, the cohort of ILD patients in which the score was derived and tested in a heterogeneous group,
and we show that the score performs similarly with individual ILD groups excluded, which make it
applicable as a screening tool for severe PH in any ILD cohort. The ILD diagnoses within the validation
cohort were slightly different to those within the derivation ILD diagnoses; however, the AUC for
predicting severe PH was similar in both (p=0.8), which strengthens these findings of applicability for all
ILD subpopulations.
The clinical utility of an echocardiographic score to predict the presence of severe group 3 PH in ILD
patients is appealing, especially as RHC is now performed less often in patients with severe ILD, mainly
due to the potential risk of invasive haemodynamic testing in patients with severe lung disease, as well as
current therapeutic limitations in these patients. In parallel, the information available from detailed PH
parameters on echocardiographic assessment is increasing. This is the largest validated score using
echocardiographic assessment of additional PH variables to identify severe PH in ILD, and has major
clinical applicability. The onset of PH in patients with lung disease (group 3 PH) [19] is adversely
prognostic, especially with the onset of severe PH and RV dysfunction [9], and is important to detect for
prognostic reasons, triaging listing for lung transplantation, and for consideration of potential targeted PH
therapies.
TABLE 4 Comparison of the derivation and validation cohorts
Derivation cohort Validation cohort p-value
Subjects 210 61
Age years 61±11 61±13 0.9
Male % 55 39 0.03
ILD diagnosis
CTD 59 (28) 33 (54) <0.001
Sarcoidosis 43 (20) 6 (10) 0.06
IPF 62 (29) 5 (8) 0.007
CHP 16 (8) 6 (10) 0.5
NSIP 16 (8) 6 (10) 0.5
Other ILD 14 (7) 5 (8) 0.7
RHC
mPAP mmHg 33±11 33±12 0.8
PVR Wood units 6.0±3.6 6.9±5.6 0.3
Cardiac output L·min-1 4.3±1.3 4.1±1.4 0.6
PCWP mmHg 10±5 10±5 0.9
BNP ng·L−1 102 (44–266) 103 (42–306) 0.7
Pulmonary function tests
FEV1 L 1.6±0.6 1.6±0.8 0.5
FEV1 % pred 58±18 62±21 0.3
FVC L 2.0±0.8 2.0±0.9 0.7
FVC % pred 60±20 65±22 0.2
TLCO % pred 25±10 27±10 0.2
KCO % pred 52±17 54±17 0.7
PaO2 kPa 7.9±1.9 8.5±2.1 0.1
CT scan
ILD extent# 20%/>20% 14/86 19/81 0.5
Data are presented as n, mean±SD or median (interquartile range), unless otherwise stated. ILD: interstital
lung disease; CTD: connective tissue disease; IPF idiopathic pulmonary fibrosis; CHP: chronic
hypersensitivity pneumonitis; NSIP: nonspecific interstitial pneumonia; RHC: right heart catheterisation;
mPAP: mean pulmonary pressure; PVR: pulmonary vascular resistance; PCWP: pulmonary capillary
wedge pressure; BNP: brain natriuretic peptide; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; TLCO: transfer factor of the lung for carbon monoxide; KCO: transfer coefficient of the lung for
carbon monoxide; PaO2: arterial oxygen tension (by capillary blood gas analysis); CT: computed
tomography. #: formal scoring of severity on CT (see methods section).
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Previous echocardiographic studies in ILD-PH have demonstrated that TRV is often unmeasurable [11, 12,
20, 21]. This is believed to relate to an alteration in the orientation of the heart due to changes in
intrathoracic pressure and suboptimal echocardiographic windows in ILD patients. In addition, a recent
echocardiographic study evaluated RHC measurements in 192 patients with advanced lung disease, 54% of
whom had ILD, where RVSP could be measured in only 52% of the cohort [22]. The authors concluded
with a good tricuspid regurgitation envelope available, TRV did reliably detect PH in advanced lung
disease, but with TRV present, the integration of other right heart abnormalities did not add to the
prediction of PH. However, 47% of patients without a measurable TRV had PH, and the presence of two
or more abnormal right heart measurements did discriminate between patients with and without PH,
especially when PH was severe (defined as mPAP ⩾35 mmHg) [22]. Our study support and extends these
findings, that TRV or RVSP is the strongest predictor of severe PH, and the integration of other PH signs
improves the detection of severe PH when TRV is not measurable.
In our study, we demonstrated that the patients with severe PH had no difference in spirometry or severity
of fibrosis seen at computed tomography compared to patients with nonsevere PH, which confirms
previous studies [2, 4], and supports the hypothesis that patients develop severe PH due to additional
factors other than the severity of parenchymal fibrosis alone. It is this observation, as well as the previous
observation that patients with severe PH have worse outcomes than patients with mild–moderate PH [9].
We believe this phenotype of PH-ILD should be studied in future trials of pulmonary vascular therapies,
making the validation of such a score useful for both clinical practice and as a research tool.
Limitations
Our study was retrospective, but subjects were consecutive and were derived from our large tertiary
population of ILD patients. Inevitably, the cohort had a high pretest probability of PH, and patients with
severe PH were relatively over-represented. The high pretest probability of PH and high proportion of
severe PH might explain the observed high rate of TRV availability (92%), which is much higher than
other published series. However, given the similar populations in previous series, we feel this is most likely
to reflect the detailed modern echocardiography studies now available. Therefore, the findings of this study
apply broadly to patients with ILD who have a clinical suspicion of PH. A large proportion of our patients
had either CTD-ILD or sarcoidosis, such that a limitation to consider is that the overall cohort might be
considered to be a less “pure” group 3 PH. However, only patients with significant fibrotic lung disease
were included. Furthermore, analysis removing the sarcoid and CTD-ILD populations in turn showed the
score behaved similarly without these subgroups. A final limitation is that the usual definition of severe
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FIGURE 3 Line plots demonstrating the effect of increasing unavailability of tricuspid regurgitation on the
echocardiographic score area under the curve (AUC) for severe pulmonary hypertension (PH) analysis and its
effect on sensitivity. Given the frequent “real-life” difficulty assessing tricuspid regurgitant velocity (TRV) at
echocardiography in interstitial lung disease (ILD) patients, models were created to demonstrate the effect of
increasing unavailability of TRV on a) the AUC of the echocardiographic score and b) the sensitivity of the
score in predicting severe PH. We simulated an increasing level of unavailable TRV by randomly blinding
available TRV values, with 100 iterations (by bootstrapping), and calculated the AUC and sensitivity following
each iteration. We tested levels of TRV unavailability ranging between 8% (observed in the original cohort) and
60% (by 1% increments). The line plots show that AUC for the echo score is preserved across a wide
spectrum of TRV unavailability (a). In addition, there was a minor reduction in the sensitivity of the score,
despite a dramatic reduction in TRV availability from 93% to 40%, as opposed to TRV alone (using a cut-off of
4 m·s−1, missing values considered ⩽4 m·s−1) with a sensitivity that is halved.
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PH in lung disease not only considers the mPAP ⩾35 mmHg, but also low cardiac output; however, the
RHC data did not have reliable cardiac output measurements from every study. We therefore felt that
using just mPAP ⩾35 mmHg in this retrospective setting, although not ideal, would be reasonable.
In summary, a RVSP >64 mmHg or a composite echocardiographic score of ⩾7 predicts severe PH with a
high sensitivity and specificity in ILD patients. The score can predict severe PH-ILD even in patients
without available TRV or RVSP. The use of this noninvasive tool should guide onward assessment at PH
and ILD centres, and help stratify patients with severe PH-ILD into much needed clinical trials. While the
stepwise echocardiographic score identifies individuals with suspected severe PH, RHC will remain
essential for confirmation.
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